Nuwellis (NUWE) Stock Price, News & Analysis

Company Overview

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Key Stats

• Today's Range: $1.00 to $1.07
• 50-Day Range: $0.98 to $2.81
• 52-Week Range: $0.92 to $30.10
• Volume: 189,113 shs
• Average Volume: 904,596 shs
• Market Capitalization: $4.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Strong Buy

Nuwellis Stock Analysis - MarketRank™

Nuwellis scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Nuwellis has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nuwellis has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nuwellis are expected to grow in the coming year, from ($9.91) to ($2.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuwellis is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuwellis is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuwellis has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.16% of the float of Nuwellis has been sold short.

Short Interest Ratio / Days to Cover

Nuwellis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuwellis has recently increased by 7.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuwellis does not currently pay a dividend.

Dividend Growth

Nuwellis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

29.16% of the float of Nuwellis has been sold short.

Short Interest Ratio / Days to Cover

Nuwellis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuwellis has recently increased by 7.58%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Nuwellis this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for NUWE on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuwellis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.60% of the stock of Nuwellis is held by insiders.

Percentage Held by Institutions

Only 3.13% of the stock of Nuwellis is held by institutions.

NUWE Stock Analysis - Frequently Asked Questions

How have NUWE shares performed this year?

Nuwellis' stock was trading at $20.3315 at the beginning of 2024. Since then, NUWE stock has decreased by 95.1% and is now trading at $1.00.
View the best growth stocks for 2024 here.

How were Nuwellis' earnings last quarter?

Nuwellis, Inc. (NASDAQ:NUWE) issued its quarterly earnings data on Monday, November, 11th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $2.62. The firm had revenue of $2.37 million for the quarter, compared to analysts' expectations of $2.40 million. Nuwellis had a negative net margin of 169.54% and a negative trailing twelve-month return on equity of 28,159.25%.

When did Nuwellis' stock split?

Nuwellis shares reverse split on the morning of Friday, June 28th 2024. The 1-35 reverse split was announced on Friday, June 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Nuwellis?

Shares of NUWE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Nuwellis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Mullen Automotive (MULN), Verb Technology (VERB), TransCode Therapeutics (RNAZ), Exela Technologies (XELA), AMC Entertainment (AMC), BIOLASE (BIOL) and Terran Orbital (LLAP).

Company Calendar

• Last Earnings: 11/11/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NUWE
• CUSIP: N/A
• CIK: 1506492
• Web: www.nuwellis.com
• Phone: (952) 345-4200
• Fax: N/A
• Employees: 59
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.00
• High Stock Price Target: $17.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +1,600.0%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($116.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,210,000.00
• Net Margins: -169.54%
• Pretax Margin: -169.47%
• Return on Equity: -28,159.25%
• Return on Assets: -207.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.03
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $8.97 million
• Price / Sales: 0.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.40 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 4,374,000
• Free Float: 4,260,000
• Market Cap: $4.37 million
• Optionable: Not Optionable
• Beta: 0.32